• Recently a Phase III study demonstrated that alectinib the

  2025-02-12

  

  Recently, a Phase III study demonstrated that alectinib, the second-generation ALK inhibitor, might have a better response to ALK-rearrangement patients than crizotinib [10]. Should alectinib replace crizotinib as the frontline treatment for ALK-rearranged patients? Or should those patients be treat

• It was also shown that of crizotinib resistance mechanisms c

  2025-02-12

  

  It was also shown that 15% of crizotinib resistance mechanisms can be due to an amplification of ALK gene while 30% are caused by a variety of secondary mutations (S1206Y, G1202R, L1196M, C1156Y, G1269A, L1152R, F1174L and 1151Tins) in ALK tyrosine kinase. These mutations can modify the conformation

• According to average serum fat content of g L Phillips

  2025-02-12

  

  According to average serum fat content of 6.9 g/L (Phillips et al., 1989) and serum dioxin level from individuals exposed to dioxins as the result of accidents in Seveso (Needham et al., 1997), Taiwan (Guo et al., 2004) and Vietnam (The Tai et al., 2011) the median serum concentration of TCDD would

• br Materials and methods br Results br Discussion This

  2025-02-12

  

  Materials and methods Results Discussion This study demonstrates that treatment with a selective adenosine kinase inhibitor ABT-702, thereby enhancing extracellular adenosine, can provide partial protection from age-related hearing loss in C57BL/6J mice. Chronic treatment with ABT-702, comm

• Until now the molecular interactions of Tmod or

  2025-02-12

  

  Until now, the molecular interactions of Tmod or Lmod with MRT67307 HCl had been assessed in pyrene-actin polymerization assays [13], [23], [27], [28], [44], [45] or directly measured using non-denaturing polyacrylamide gel-electrophoresis (for Tmod isoforms only [23]), ITC (for Tmod1 and Lmod2) [4

• g15 br Conflict of interest br Acknowledgments

  2025-02-12

  

  Conflict of interest Acknowledgments This work was supported by research grant [PR26/20326] from Santander Bank/UCM. The authors would like to thank Miguel Capo, Professor of Toxicology from the Universidad Complutense de Madrid, for his counseling during the preparation of the present work.

• br Research perspective In vitro and

  2025-02-11

  

  Research perspective In vitro and in vivo studies have demonstrated that increased LPA/ATX signaling contributes to cancer initiation and progression. Recent findings on the role of non-tumoral ATX in cancer progression and metastasis highlighted a new functional contribution for the microenviron

• Jesus et al discovered a new series of azaindole

  2025-02-11

  

  Jesus et al. discovered a new series of azaindole as Aurora inhibitors through various modification of GSK1070916 (47). They synthesized series from modification of the GSK1070916 and evaluated for in-vitro Aurora-B/INCENP and Aurora-A/TPX2 inhibition assays. Modified vasopressin receptor 48 and 49

• In the last decade the zebrafish has

  2025-02-11

  

  In the last decade, the zebrafish has emerged as a valuable vertebrate model to systematically dissect the genetic underpinnings of both vertebrate heart development and function [8,9], as well as distinct cardiac diseases such as congenital heart disease [10], cardiomyopathies [11,12] and cardiac a

• br Experimental section br Competing interests br

  2025-02-11

  

  Experimental section Competing interests Author's contributions Acknowledgement This research is partially supported by a seed fund for the Center for Drug Discovery and Translational Research (LS) and a research grant by Fujifilm (VPS and LS). The Sponsors played no roles in study desig

• Many ruthenium complexes were tested as potential anticancer

  2025-02-11

  

  Many ruthenium complexes were tested as potential anticancer agents and two complexes, namely NAMI-A (trans-[imH] [RuCl4(dmso-S)(im)]; im, imidazole) and KP1019 (trans-[indH][RuCl4(ind)2]; ind, indazole) have successfully entered clinical trials [27], [28]. NAMI-A is selectively active against metas

• br ASK in Huntington s disease and other

  2025-02-11

  

  ASK1 in Huntington's disease and other polyglutamine diseases The polyglutamine (polyQ) diseases are a group of inherited neurodegenerative disorders caused by the expansion of cytosine-adenine-guanine (CAG) trinucleotide repeats in the coding regions of specific genes, leading to the production

• br Results Of the U S jurisdictions surveyed Table

  2025-02-11

  

  Results Of the 51 U.S. jurisdictions surveyed (Table 1), 33 reported that hyperargininemia is one of the conditions for which all newborns are required to be screened, with the earliest screening reported in Massachusetts in 1999. Of the 18 other jurisdictions, an additional 5 reported that hyper

• br Apelin The APJ receptor ligand

  2025-02-11

  

  Apelin The APJ receptor ligand apelin firstly in 1998 was segregated from bovine stomach tissue. Human preproapelin gene located on chromosome Xq25–26.1. The apelin preproproteins consist of 77 amino PRIMA-1MET residues that are cleaved into biologically active C-terminal fragments of various si

• br Conclusion br Competing interests br Funding The Bolger

  2025-02-11

  

  Conclusion Competing interests Funding The Bolger Prostate Cancer Research Fund (no grant number), the National Institute of General Medical Sciences of the National Institutes of Health (1-R01-GM58553, G. B. Bolger, principal investigator), and the National Cancer Institute of the NIH to t

15855 records 20/1057 page Previous Next First page 上5页 1617181920 下5页 Last page